BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

706 related articles for article (PubMed ID: 28252173)

  • 1. Inhibition of miR-660-5p expression suppresses tumor development and metastasis in human breast cancer.
    Shen Y; Ye YF; Ruan LW; Bao L; Wu MW; Zhou Y
    Genet Mol Res; 2017 Feb; 16(1):. PubMed ID: 28252173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-99a-5p suppresses breast cancer progression and cell-cycle pathway through downregulating CDC25A.
    Qin H; Liu W
    J Cell Physiol; 2019 Apr; 234(4):3526-3537. PubMed ID: 30443946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-199a-5p confers tumor-suppressive role in triple-negative breast cancer.
    Chen J; Shin VY; Siu MT; Ho JC; Cheuk I; Kwong A
    BMC Cancer; 2016 Nov; 16(1):887. PubMed ID: 27842518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1.
    Chen LL; Zhang ZJ; Yi ZB; Li JJ
    Br J Cancer; 2017 Jun; 117(1):78-88. PubMed ID: 28571042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-17-5p promotes human breast cancer cell migration and invasion through suppression of HBP1.
    Li H; Bian C; Liao L; Li J; Zhao RC
    Breast Cancer Res Treat; 2011 Apr; 126(3):565-75. PubMed ID: 20505989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-409-5p is upregulated in breast cancer and its downregulation inhibits cancer development through downstream target of RSU1.
    Yu H; Xing H; Han W; Wang Y; Qi T; Song C; Xu Z; Li H; Huang Y
    Tumour Biol; 2017 May; 39(5):1010428317701647. PubMed ID: 28459205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-340 inhibits the migration, invasion, and metastasis of breast cancer cells by targeting Wnt pathway.
    Mohammadi-Yeganeh S; Paryan M; Arefian E; Vasei M; Ghanbarian H; Mahdian R; Karimipoor M; Soleimani M
    Tumour Biol; 2016 Jul; 37(7):8993-9000. PubMed ID: 26758430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-671-5p inhibits epithelial-to-mesenchymal transition by downregulating FOXM1 expression in breast cancer.
    Tan X; Fu Y; Chen L; Lee W; Lai Y; Rezaei K; Tabbara S; Latham P; Teal CB; Man YG; Siegel RS; Brem RF; Fu SW
    Oncotarget; 2016 Jan; 7(1):293-307. PubMed ID: 26588055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-411-5p inhibits proliferation and metastasis of breast cancer cell via targeting GRB2.
    Zhang Y; Xu G; Liu G; Ye Y; Zhang C; Fan C; Wang H; Cai H; Xiao R; Huang Z; Luo Q
    Biochem Biophys Res Commun; 2016 Aug; 476(4):607-613. PubMed ID: 27264952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer.
    Li J; Lai Y; Ma J; Liu Y; Bi J; Zhang L; Chen L; Yao C; Lv W; Chang G; Wang S; Ouyang M; Wang W
    BMC Cancer; 2017 Nov; 17(1):745. PubMed ID: 29126392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo and in vitro effects of microRNA-27a on proliferation, migration and invasion of breast cancer cells through targeting of SFRP1 gene via Wnt/β-catenin signaling pathway.
    Kong LY; Xue M; Zhang QC; Su CF
    Oncotarget; 2017 Feb; 8(9):15507-15519. PubMed ID: 28099945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-424-5p regulates cell proliferation, migration and invasion by targeting doublecortin-like kinase 1 in basal-like breast cancer.
    Wang J; Wang S; Zhou J; Qian Q
    Biomed Pharmacother; 2018 Jun; 102():147-152. PubMed ID: 29550638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RhoC is a major target of microRNA-93-5P in epithelial ovarian carcinoma tumorigenesis and progression.
    Chen X; Chen S; Xiu YL; Sun KX; Zong ZH; Zhao Y
    Mol Cancer; 2015 Feb; 14(1):31. PubMed ID: 25649143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-125a-5p plays a role as a tumor suppressor in lung carcinoma cells by directly targeting STAT3.
    Zhong L; Sun S; Shi J; Cao F; Han X; Chen Z
    Tumour Biol; 2017 Jun; 39(6):1010428317697579. PubMed ID: 28631574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppressive role of miR-502-5p in breast cancer via downregulation of TRAF2.
    Sun LL; Wang J; Zhao ZJ; Liu N; Wang AL; Ren HY; Yang F; Diao KX; Fu WN; Wan EH; Mi XY
    Oncol Rep; 2014 May; 31(5):2085-92. PubMed ID: 24677135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-493-5p attenuates the invasiveness and tumorigenicity in human breast cancer by targeting FUT4.
    Zhao L; Feng X; Song X; Zhou H; Zhao Y; Cheng L; Jia L
    Oncol Rep; 2016 Aug; 36(2):1007-15. PubMed ID: 27375041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-139-5p inhibits the biological function of breast cancer cells by targeting Notch1 and mediates chemosensitivity to docetaxel.
    Zhang HD; Sun DW; Mao L; Zhang J; Jiang LH; Li J; Wu Y; Ji H; Chen W; Wang J; Ma R; Cao HX; Wu JZ; Tang JH
    Biochem Biophys Res Commun; 2015 Oct; 465(4):702-13. PubMed ID: 26299922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circular RNA hsa_circ_0052112 promotes cell migration and invasion by acting as sponge for miR-125a-5p in breast cancer.
    Zhang HD; Jiang LH; Hou JC; Zhong SL; Zhou SY; Zhu LP; Li J; Wang DD; Sun DW; Ji ZL; Tang JH
    Biomed Pharmacother; 2018 Nov; 107():1342-1353. PubMed ID: 30257349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [miR-101 inhibits the proliferation and migration of breast cancer cells via downregulating the expression of DNA methyltransferase 3a].
    Liu J; Pang Y; Wang H; Li Y; Sun X; Xu F; Ren H; Liu D
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Mar; 32(3):299-303. PubMed ID: 26927545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-361-5p inhibits glycolytic metabolism, proliferation and invasion of breast cancer by targeting FGFR1 and MMP-1.
    Ma F; Zhang L; Ma L; Zhang Y; Zhang J; Guo B
    J Exp Clin Cancer Res; 2017 Nov; 36(1):158. PubMed ID: 29132384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.